Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.48 |
| ▸ | METAP1 | P53582 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.41 |
| ▸ | FNTA | P49354 | 5/20 | 0.41 |
| ▸ | FNTB | P49356 | 5/20 | 0.41 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.41 |
| ▸ | BHMT | Q93088 | 2/20 | 0.41 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | CPA1 | P15085 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | CTSC | P53634 | 2/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8661911 | 1.00 | METAP2 (0.48) | METAP2METAP1LMNARNPEPDPP4 | |
| SCHEMBL8936813 | 1.00 | METAP2 (0.48) | METAP2METAP1LMNARNPEPDPP4 | |
| SCHEMBL30051498 | 0.97 | METAP2 (0.46) | METAP2METAP1LMNARNPEPDPP4 | |
| Formic Acid SCHEMBL20489091 | 0.94 | METAP2 (0.44) | METAP2METAP1LMNARNPEPDPP4 | |
| SCHEMBL29349967 | 0.92 | LMNA (0.45) | METAP2METAP1LMNAFNTAFNTB | |
| SCHEMBL30052878 | 0.91 | FNTA (0.48) | METAP2METAP1LMNARNPEPFNTA | |
| SCHEMBL30112746 | 0.90 | METAP2 (0.41) | METAP2METAP1LMNAFNTAFNTB | |
| SCHEMBL30011954 | 0.90 | LMNA (0.43) | METAP2METAP1LMNAFNTAFNTB | |
| SCHEMBL30051396 | 0.89 | CTSD (0.47) | METAP2METAP1LMNAFNTAFNTB | |
| SCHEMBL29497578 | 0.87 | METAP2 (0.40) | METAP2METAP1LMNAFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4529540-A1 | HER2-BINDING AGENTS AND USES THEREOF | Cereius, Inc. (US) | 2025-04-02 | — | — | EP | claimed |
| CN-119604536-A | HER2 binding agents and uses thereof | 塞雷乌斯股份有限公司 | 2025-03-11 | — | — | CN | claimed |
| US-20250011340-A1 | BENZODIAZEPINE DERIVATIVES AND ANTIBODY CONJUGATES THEREOF | IMMUNOGEN, INC. | 2025-01-09 | — | — | US | claimed |
| US-20240426830-A1 | CHRONIC WOUND HEALING BIOMARKER DIAGNOSTICS | THE TRUSTEES OF INDIANA UNIVERSITY | 2024-12-26 | — | — | US | claimed |
| CN-113769108-B | Conjugates of cysteine engineered antibodies | 伊缪诺金公司 | 2024-11-08 | — | — | CN | claimed |
| US-20240307428-A1 | SYNERGISTIC COMPOSITION FOR MAINTENANCE OF HEALTHY BALANCE OF MICROFLORA | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2024-09-19 | — | — | US | claimed |
| US-12050228-B2 | Automated sample quality assessment | METABOLON, INC. (US) | 2024-07-30 | — | — | US | claimed |
| US-12029748-B2 | Synergistic composition for maintenance of healthy balance of microflora | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2024-07-09 | — | — | US | claimed |
| EP-4374850-A2 | METHODS OF PREVENTING METHIONINE OXIDATION IN IMMUNOCONJUGATES | ImmunoGen, Inc. (US) | 2024-05-29 | — | — | EP | claimed |
| US-11897961-B2 | Anti-CD123 antibodies and conjugates and derivatives thereof | IMMUNOGEN, INC. (US) | 2024-02-13 | — | — | US | claimed |
| CN-106604927-B | Cytotoxic benzodiazepine derivatives | 伊缪诺金公司 | 2022-08-09 | — | — | CN | claimed |
| US-20220242912-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2022-08-04 | — | — | US | claimed |
| US-11332535-B2 | Anti-CD123 antibodies and conjugates and derivatives thereof | IMMUNOGEN, INC. (US) | 2022-05-17 | — | — | US | claimed |
| US-11332497-B2 | Therapeutic peptides | COHBAR, INC. (US) | 2022-05-17 | — | — | US | claimed |
| EP-3941527-A1 | METHODS OF PREPARING CELL-BINDING AGENT-DRUG CONJUGATES | ImmunoGen, Inc. (US) | 2022-01-26 | — | — | EP | claimed |
| US-20210088539-A1 | AUTOMATED SAMPLE QUALITY ASSESSMENT | METABOLON, INC. | 2021-03-25 | — | — | US | claimed |
| US-10890592-B2 | Automated sample quality assessment | METABOLON, INC. (US) | 2021-01-12 | — | — | US | claimed |
| WO-1995021191-A1 | BIOLUMINESCENT INDICATOR BASED UPON THE EXPRESSION OF A GENE FOR A MODIFIED GREEN-FLUORESCENT PROTEIN | WARD WILLIAM (US) | 1995-08-10 | — | — | WO | claimed |
| EP-0412061-B1 | 2-(N-acyl)amino-6,7-dimethoxy tetralines, process for their preparation and pharmaceutical compositions having antihypertensive activity containing same | SIGMA TAU IND FARMACEUTI (IT) | 1994-10-05 | — | — | EP | claimed |
| US-4024286-A | Fortification of foodstuffs with C-terminal amino acid substituted methionine dipeptides | MILES LABORATORIES, INC. (US) | 1977-05-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11897961-B2 | Anti-CD123 antibodies and conjugates and derivatives thereof | IL23R, CD22, IL2RA | METAP2 3503/4885METAP1 3023/4885LMNA 2683/4885 |
| US-20250011340-A1 | BENZODIAZEPINE DERIVATIVES AND ANTIBODY CONJUGATES THEREOF | GABRA6, GABRA2, GABRA1 | METAP2 3588/4885METAP1 3423/4885LMNA 3480/4885 |
| US-11332535-B2 | Anti-CD123 antibodies and conjugates and derivatives thereof | IL23R, CD22, IL2RA | METAP2 3503/4885METAP1 3023/4885LMNA 2683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.